These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

373 related items for PubMed ID: 29894814

  • 1. Permeability of glibenclamide through a PAMPA membrane: The effect of co-amorphization.
    Ruponen M, Visti M, Ojarinta R, Laitinen R.
    Eur J Pharm Biopharm; 2018 Aug; 129():247-256. PubMed ID: 29894814
    [Abstract] [Full Text] [Related]

  • 2. The effect of co-amorphization of glibenclamide on its dissolution properties and permeability through an MDCKII-MDR1 cell layer.
    Sormunen H, Ruponen M, Laitinen R.
    Int J Pharm; 2019 Oct 30; 570():118653. PubMed ID: 31472218
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Amino acids as co-amorphous excipients for simvastatin and glibenclamide: physical properties and stability.
    Laitinen R, Löbmann K, Grohganz H, Strachan C, Rades T.
    Mol Pharm; 2014 Jul 07; 11(7):2381-9. PubMed ID: 24852326
    [Abstract] [Full Text] [Related]

  • 5. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
    Löbmann K, Grohganz H, Laitinen R, Strachan C, Rades T.
    Eur J Pharm Biopharm; 2013 Nov 07; 85(3 Pt B):873-81. PubMed ID: 23537574
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Co-Amorphous Formulations of Furosemide with Arginine and P-Glycoprotein Inhibitor Drugs.
    Ruponen M, Kettunen K, Santiago Pires M, Laitinen R.
    Pharmaceutics; 2021 Jan 27; 13(2):. PubMed ID: 33514009
    [Abstract] [Full Text] [Related]

  • 8. Co-former selection for co-amorphous drug-amino acid formulations.
    Kasten G, Löbmann K, Grohganz H, Rades T.
    Int J Pharm; 2019 Feb 25; 557():366-373. PubMed ID: 30578980
    [Abstract] [Full Text] [Related]

  • 9. Dipeptides as co-formers in co-amorphous systems.
    Wu W, Löbmann K, Schnitzkewitz J, Knuhtsen A, Pedersen DS, Rades T, Grohganz H.
    Eur J Pharm Biopharm; 2019 Jan 25; 134():68-76. PubMed ID: 30468836
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. New metastable form of glibenclamide prepared by redispersion from ternary solid dispersions containing polyvinylpyrrolidone-K30 and sodium lauryl sulfate.
    Thongnopkoon T, Puttipipatkhachorn S.
    Drug Dev Ind Pharm; 2016 Jan 25; 42(1):70-79. PubMed ID: 25835067
    [Abstract] [Full Text] [Related]

  • 12. The effect of drug and EUDRAGIT® S 100 miscibility in solid dispersions on the drug and polymer dissolution rate.
    Higashi K, Hayashi H, Yamamoto K, Moribe K.
    Int J Pharm; 2015 Oct 15; 494(1):9-16. PubMed ID: 26253374
    [Abstract] [Full Text] [Related]

  • 13. Tannic acid as a co-former in co-amorphous systems: Enhancing their physical stability, solubility and dissolution behavior.
    Fael H, Demirel AL.
    Int J Pharm; 2020 May 15; 581():119284. PubMed ID: 32243965
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Transformations between Co-Amorphous and Co-Crystal Systems and Their Influence on the Formation and Physical Stability of Co-Amorphous Systems.
    Wu W, Wang Y, Löbmann K, Grohganz H, Rades T.
    Mol Pharm; 2019 Mar 04; 16(3):1294-1304. PubMed ID: 30624075
    [Abstract] [Full Text] [Related]

  • 18. Dissolution properties of co-amorphous drug-amino acid formulations in buffer and biorelevant media.
    Heikkinen AT, DeClerck L, Löbmann K, Grohganz H, Rades T, Laitinen R.
    Pharmazie; 2015 Jul 04; 70(7):452-7. PubMed ID: 26373205
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Solid-state properties and dissolution behaviour of tablets containing co-amorphous indomethacin-arginine.
    Lenz E, Jensen KT, Blaabjerg LI, Knop K, Grohganz H, Löbmann K, Rades T, Kleinebudde P.
    Eur J Pharm Biopharm; 2015 Oct 04; 96():44-52. PubMed ID: 26197392
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.